Gilead Sciences, working together with China authorities, has started a China trial of its antiviral remdesivir as a treatment for 2019-nCoV coronavirus. The trial will enroll 270 patients and be based in the China-Japan Friendship Hospital in Beijing. It is a Phase III randomized, double-blind, placebo-controlled multicenter study that will evaluate the efficacy and safety of remdesivir in hospitalized adult patients with mild and moderate 2019-nCoV infections. Researchers expect to complete the trial on April 27. Gilead said remdesivir has previously shown efficacy in models of the MERS and SARS coronaviruses.
Source: China Biotoday
